LDN-193189 dihydrochloride | B2986

LDN-193189 inhibits transcriptional activity of the (Bone Morphogenetic Protein) BMP type I receptors known as activin receptor-like kinases (ALKs). It inhibits ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM respectively and shows weaker effects on activin and the TGF-β type I receptors ALK4, ALK5 and ALK7. It inhibits phosphorylation of the BMP signaling effectors SMAD1, SMAD5 and SMAD8 with IC₅₀ value of 5 nM. LDN-193189 significantly reduces tumor growth in SCID mice bearing MDA-PCa-118b tumors.

LDN-193189 inhibits transcriptional activity of the (Bone Morphogenetic Protein) BMP type I receptors known as activin receptor-like kinases (ALKs). It inhibits ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM respectively and shows weaker effects on activin and the TGF-β type I receptors ALK4, ALK5 and ALK7. It inhibits phosphorylation of the BMP signaling effectors SMAD1, SMAD5 and SMAD8 with IC₅₀ value of 5 nM. LDN-193189 significantly reduces tumor growth in SCID mice bearing MDA-PCa-118b tumors.

B2986 | LDN-193189 dihydrochloride DataSheet

Alternate Name/Synonyms: 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline,dihydrochloride

Appearance: Yellow Powder

Formulation:

CAS Number: 1435934-00-1

Structure Available?: True

Peptide sequence:

Salt Form: True

Molecular Formula: C₂₅H₂₄Cl₂N₆

Molecular Weight: 479.409

Cell-Permeable?: True

Purity: >98%

Solubilities: ~5 mg/ml in DMSO

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: An inhibitor of BMP receptor 1

MDL Number: MFCD23098917

PubChem CID: 91900717

SMILES: C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3.Cl.Cl

InChi: InChI=1S/C25H22N6.2ClH/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30;;/h1-10,15-17,26H,11-14H2;2*1H

InChi Key: CMQXLLAILGGLRV-UHFFFAOYSA-N